Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06239324
PHASE1/PHASE2

Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser

Sponsor: Egymedicalpedia

View on ClinicalTrials.gov

Summary

Alopecia areata (AA) an autoimmune disorder of hair follicles results in varying degrees of scalp, facial and body hair loss. Clinically, patients' presentation varies from patchy circumscribed scalp involvement to total body and scalp hair loss affects up to 2% of the general population. The exact pathobiology of AA has still remained elusive, while the common theory is the collapse of the immune privilege of the hair follicle caused by immunological mechanism. Multiple genetic, environment factors and psychological stress contribute to the pathogenesis of Alopecia Areata . Recent insights into the pathogenesis of AA have led to the development of new treatment strategies, such as Janus kinase inhibitors, biologics and several small molecular agents. In addition, modern therapies for AA, including antihistamines, platelet-rich plasma injection

Official title: Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser Versus Microneedling in Alopecia Areata Treatment

Key Details

Gender

All

Age Range

30 Years - 35 Years

Study Type

INTERVENTIONAL

Enrollment

70

Start Date

2024-02-01

Completion Date

2024-05-01

Last Updated

2024-04-16

Healthy Volunteers

No

Conditions

Interventions

DRUG

Latanoprost

Comparing between Erbium YAG laser assisted drug delivery of latanoprost versus transepidermal latanoprost delivery by microneedling in alopecia areata treatment for all participants.

Locations (1)

Qena Hospital

Qina, Egypt